MBP and myeloid sarcoma: However, it was noted that an APL that served as an antagonist in vitro would induce EAE in vivo demonstrating that one peptide could be an antagonist for clone A but an agonist for clone B. Subsequent clinical trials of immunotherapy with an APL from MBP:83-99 led to disease exacerbation in an individual with MS [15].